ENDRA Life Sciences (NASDAQ:NDRA) Releases Quarterly Earnings Results, Misses Expectations By $0.18 EPS

ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) posted its earnings results on Monday. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.18), FiscalAI reports.

ENDRA Life Sciences Trading Up 0.5%

Shares of NDRA traded up $0.02 during trading hours on Monday, reaching $4.43. 4,492 shares of the stock traded hands, compared to its average volume of 51,423. The stock has a fifty day simple moving average of $5.32 and a 200 day simple moving average of $4.82. ENDRA Life Sciences has a 52 week low of $2.96 and a 52 week high of $6.95. The company has a market cap of $6.64 million, a price-to-earnings ratio of -0.69 and a beta of -0.07.

Analysts Set New Price Targets

Separately, Weiss Ratings cut ENDRA Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, November 2nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $25.00.

Read Our Latest Report on NDRA

About ENDRA Life Sciences

(Get Free Report)

ENDRA Life Sciences is a medical technology company developing imaging tools for the assessment of liver disease. Its technology is designed to provide clinicians with a non-invasive way to evaluate liver tissue and support the monitoring of conditions such as fatty liver disease. The company’s lead platform, TAEUS (Thermo-Acoustic Enhanced Ultrasound), combines radiofrequency energy with ultrasound to measure tissue characteristics, including liver fat. ENDRA is developing the system as an alternative or complement to existing approaches to liver assessment.

Further Reading

Earnings History for ENDRA Life Sciences (NASDAQ:NDRA)

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.